ArticleInternational ophthalmology2026
Non-surgical management of thyroid eye disease: a pilot survey of oculoplastic surgeons.
Article in International ophthalmology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo investigate real-world practices in the non-surgical management of thyroid eye disease (TED) among oculoplastic surgeons across participating Asia-Pacific clinical settings.
methodsA structured 39-item online questionnaire was distributed between August and October 2023 to 40 eligible oculoplastic surgeons identified through the Asia Pacific Society of Ophthalmic Plastic and Reconstructive Surgery. The questionnaire assessed clinical experience, TED patient volume, and preferred non-surgical therapeutic approaches, including corticosteroids, immunosuppressive agents, orbital radiotherapy (ORT), biologic therapies, periocular injections, and micronutrient supplementation. Descriptive statistics were used because of the exploratory nature and small sample size of the survey.
resultsSeventeen physicians completed the questionnaire, corresponding to a response rate of 42.5%. All respondents reported using glucocorticoids, and intravenous methylprednisolone was the predominant systemic treatment. A cumulative dose of 4.5 g, administered as 6 weekly infusions of 500 mg followed by 6 weekly infusions of 250 mg, was selected by 13 respondents (76.5%). Periocular injections were used by 11 respondents (64.7%), with triamcinolone acetonide being the most frequently used agent. Ten respondents (58.8%) reported using ORT. Immunosuppressive agents were used less frequently, with mycophenolate mofetil and methotrexate each reported by 3 respondents (17.7%). Biologic therapies included tocilizumab (4, 23.5%), rituximab (3, 17.7%), and teprotumumab (1, 5.9%). Selenium supplementation was reported only sporadically.
conclusionsThis exploratory survey demonstrates substantial variability in the non-surgical management of TED across participating Asia-Pacific settings. Given the small, non-random sample and uneven country representation, these findings should be interpreted as preliminary and hypothesis-generating rather than representative of the Asia-Pacific region as a whole.
Indexed as
Identifiers
42886427What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.